Autobahn raises $100M on investor interest in neuropsych drugs
San Diego biotechnology company Autobahn Therapeutics on Wednesday said it raised $100 million to advance an experimental mood disorder medicine into mid-stage testing. The company, which launched in 2020, is developing the drug for major depressive …